Japan’s MHLW Approves Optical Topography Imaging As Advanced Medical Technology
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare approved March 10 optical topography imaging as a class two advanced medical technology. The testing is indicated to diagnose patients showing symptoms of depression, bipolar disorder and schizophrenia. Depression caused by organic disease is excluded. The expert council at the MHLW considers the imaging technology relatively effective compared to current technology. The Ministry plans to apply medical insurance for the diagnostic beginning April 1. After insurance coverage, patients will pay ¥13,000 for a regular testing. The approval condition for medical facilities is to establish at least one neurological physician and one clinical technologist. (Click here for more - Japanese language
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.